Evidence map›Paper›PMID 41737044›Full record

ReviewInternational journal of nanomedicine2026

Nano-Reagents in Acute Pancreatitis: Diagnostic, Therapeutic, and Theranostic Advances.

Xiao Yang, Qing Li, Lixuan Tang, Li Huang, Chaogeng Zhu, Qingshan Chen

Abstract readReview
In one paragraph

Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xiao Yang *The Department of Oncology, The First Hospital of Hunan University of Chinese Medicine, Changsha, People's Republic of China.
Qing Li *School of Medicine, Hunan University of Chinese Medicine, Changsha, People's Republic of China.
Lixuan TangSchool of Medicine, Hunan University of Chinese Medicine, Changsha, People's Republic of China.
Li HuangThe Department of Preparation Center, The First Hospital of Hunan University of Chinese Medicine, Changsha, People's Republic of China.
Chaogeng ZhuThe Department of Hepatobiliary Pancreatic Hernia Surgery, The First Hospital of Hunan University of Chinese Medicine, Changsha, People's Republic of China.
Qingshan ChenThe Department of Hepatobiliary Pancreatic Hernia Surgery, The First Hospital of Hunan University of Chinese Medicine, Changsha, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This narrative review synthesizes the latest advances in nano-diagnostic and therapeutic reagents for acute pancreatitis (AP), based on peer-reviewed experimental and preclinical studies published in recent years. AP endangers life through self-digestion of pancreatic tissue and a cascading systemic inflammatory reaction. In clinical practice, the existing diagnostic and therapeutic tools are limited by low sensitivity and insufficient targeting, so it is difficult to achieve the ideal diagnosis and treatment effect of AP. However, the emerging nanotechnology is expected to overcome these drawbacks by offering highly specific delivery systems and ultrasensitive detection platforms. The studies included in this review are directly related to nanomedicine diagnosis, treatment, and diagnosis and treatment of AP, and are categorized by their functional implementation pathways to emphasize technological translational potential. For diagnosis, nano-sensors (optical, electrochemical) and contrast agents (MRI-responsive nanoparticles) enable early detection of biomarkers and precise imaging of pancreatic lesions. For treatment, nano-reagents address barriers like the blood-pancreatic barrier, low drug specificity, and insufficient intervention in the pathogenesis through multi-faceted strategies: targeted delivery systems, microenvironment-responsive release, and biological pathway regulation. Theranostic nano-reagents integrating diagnosis and therapy show promise for real-time monitoring and intervention. In the end, it emphasizes the need for further optimization of biocompatibility and clinical validation and provides insights for clinical strategy design.

Indexed as

NanoparticlesPancreatitisTheranostic NanomedicineAcute DiseaseAnimalsBiomarkersContrast MediaDrug Delivery SystemsHumansNanomedicineBiomarkersContrast Mediaacute pancreatitisdiagnosisnanomedicinenano-reagenttherapy

Identifiers

PMID41737044
PMCPMC12927850

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.